Cargando…

Fixed drug eruption after the Sinopharm COVID‐19 vaccine

After coronavirus disease 2019 (COVID‐19) became widespread around the world, several vaccines have been developed with variable efficacy and potency and based on different platforms to control the pandemic. One of these vaccines is Sinopharm (BBIBP‐CorV), which is an inactivated virus that was rele...

Descripción completa

Detalles Bibliográficos
Autores principales: Rekabi, Mahsa, Sadati, Elham, Mirzaei, Jamal, Pourdowlat, Guitti, Velayati, Ali Akbar, Honarpisheh, Parisa
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9349928/
http://dx.doi.org/10.1002/jvc2.40
_version_ 1784762163913555968
author Rekabi, Mahsa
Sadati, Elham
Mirzaei, Jamal
Pourdowlat, Guitti
Velayati, Ali Akbar
Honarpisheh, Parisa
author_facet Rekabi, Mahsa
Sadati, Elham
Mirzaei, Jamal
Pourdowlat, Guitti
Velayati, Ali Akbar
Honarpisheh, Parisa
author_sort Rekabi, Mahsa
collection PubMed
description After coronavirus disease 2019 (COVID‐19) became widespread around the world, several vaccines have been developed with variable efficacy and potency and based on different platforms to control the pandemic. One of these vaccines is Sinopharm (BBIBP‐CorV), which is an inactivated virus that was released by Sinopharm's Beijing institute in the summer of 2020. The most commonly reported side effects of the Sinopharm vaccine have included pain at the injection site, muscle pain, headache and fatigue. Dermatological reactions are also reported as less common and were mainly local injection site reactions. Fixed drug eruption (FDE) is a rare and unusual adverse effect and accounts for less than 1% of all severe acute respiratory syndrome coronavirus 2 vaccine‐related cutaneous manifestations. FDE has not been reported following the COVID‐19 inactivated vaccine. Here, we describe a rare case of FDE following the administration of the first shot of the Sinopharm vaccine.
format Online
Article
Text
id pubmed-9349928
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher John Wiley and Sons Inc.
record_format MEDLINE/PubMed
spelling pubmed-93499282022-08-04 Fixed drug eruption after the Sinopharm COVID‐19 vaccine Rekabi, Mahsa Sadati, Elham Mirzaei, Jamal Pourdowlat, Guitti Velayati, Ali Akbar Honarpisheh, Parisa JEADV Clinical Practice Case Reports After coronavirus disease 2019 (COVID‐19) became widespread around the world, several vaccines have been developed with variable efficacy and potency and based on different platforms to control the pandemic. One of these vaccines is Sinopharm (BBIBP‐CorV), which is an inactivated virus that was released by Sinopharm's Beijing institute in the summer of 2020. The most commonly reported side effects of the Sinopharm vaccine have included pain at the injection site, muscle pain, headache and fatigue. Dermatological reactions are also reported as less common and were mainly local injection site reactions. Fixed drug eruption (FDE) is a rare and unusual adverse effect and accounts for less than 1% of all severe acute respiratory syndrome coronavirus 2 vaccine‐related cutaneous manifestations. FDE has not been reported following the COVID‐19 inactivated vaccine. Here, we describe a rare case of FDE following the administration of the first shot of the Sinopharm vaccine. John Wiley and Sons Inc. 2022-06-29 /pmc/articles/PMC9349928/ http://dx.doi.org/10.1002/jvc2.40 Text en © 2022 The Authors. JEADV Clinical Practice published by John Wiley & Sons Ltd on behalf of European Academy of Dermatology and Venereology. https://creativecommons.org/licenses/by/4.0/This is an open access article under the terms of the http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited.
spellingShingle Case Reports
Rekabi, Mahsa
Sadati, Elham
Mirzaei, Jamal
Pourdowlat, Guitti
Velayati, Ali Akbar
Honarpisheh, Parisa
Fixed drug eruption after the Sinopharm COVID‐19 vaccine
title Fixed drug eruption after the Sinopharm COVID‐19 vaccine
title_full Fixed drug eruption after the Sinopharm COVID‐19 vaccine
title_fullStr Fixed drug eruption after the Sinopharm COVID‐19 vaccine
title_full_unstemmed Fixed drug eruption after the Sinopharm COVID‐19 vaccine
title_short Fixed drug eruption after the Sinopharm COVID‐19 vaccine
title_sort fixed drug eruption after the sinopharm covid‐19 vaccine
topic Case Reports
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9349928/
http://dx.doi.org/10.1002/jvc2.40
work_keys_str_mv AT rekabimahsa fixeddrugeruptionafterthesinopharmcovid19vaccine
AT sadatielham fixeddrugeruptionafterthesinopharmcovid19vaccine
AT mirzaeijamal fixeddrugeruptionafterthesinopharmcovid19vaccine
AT pourdowlatguitti fixeddrugeruptionafterthesinopharmcovid19vaccine
AT velayatialiakbar fixeddrugeruptionafterthesinopharmcovid19vaccine
AT honarpishehparisa fixeddrugeruptionafterthesinopharmcovid19vaccine